Publications by Dr Michael Tilby - ePrints

Browsing publications by Dr Michael Tilby.

Newcastle Authors	Title	Year
Nidal Boulos Dr Michael Tilby Professor Deborah Tweddle Professor John Lunec	Identification and characterisation of STMN4 and ROBO2 gene involvement in neuroblastoma cell differentiation	2013
Dr Ian Cowell Dr Michael Tilby Professor Caroline Austin	An overview of the visualisation and quantitation of low and high MW DNA adducts using the trapped in agarose DNA immunostaining (TARDIS) assay	2011
Professor Caroline Austin Dr Ian Cowell Dr Michael Tilby	Visualisation and quantitation of DNA adducts using the Trapped in Agarose DNA immunostaining (TARDIS) assay	2010
Dr Michael Tilby	Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells	2009
Dr Michael Tilby	Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents	2009
Dr Celine Roche Professor Steve Wedge Professor Herbie Newell Dr Michael Tilby	The kinase inhibitor O⁶-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2	2009
Andrew Jobson Dr Elaine Willmore Dr Michael Tilby Professor Caroline Austin	Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases	2008
Dr Michael Tilby	Substituted β-cyclodextrin and calix[4]arene as encapsulatory vehicles for platinum(II)-based DNA intercalators	2008
Professor Gareth Veal Julie Errington Dr Michael Tilby Professor Alan Boddy	Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours	2007
Dr Ian Cowell Dr Nicola Sunter Professor Caroline Austin Professor barbara Durkacz Dr Michael Tilby et al.	γH2AX foci form preferentially in euchromatin after ionising-radiation	2007
Jessie Jeyapalan Dr Gabriele Saretzki Alan Leake Dr Michael Tilby Professor Thomas von Zglinicki et al.	Neuroblastoma cell apoptosis induction after cisplatin treatment is not telomere–dependent	2006
Jessie Jeyapalan Dr Gabriele Saretzki Alan Leake Dr Michael Tilby Professor Thomas von Zglinicki et al.	Tumour-cell apoptosis after cisplatin treatment is not telomere dependent	2006
Annie Parry Dr Michael Tilby Professor Dianne Ford Emerita Professor Suzanne Cholerton Professor Andrew Pearson et al.	Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer	2005
Dr Ian Cowell Professor barbara Durkacz Dr Michael Tilby	Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectsia mutated	2005
Dr Emma Meczes Ali Azim-Araghi Dr Michael Tilby	Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA	2005
Dr Michael Tilby	The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136	2005
Dr Elaine Willmore Dr Nicola Sunter Dr Michael Tilby Professor Graham Jackson Professor Caroline Austin et al.	A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia	2004
Professor Gareth Veal Dr Michael Tilby	A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia	2004
Fiona Errington Dr Elaine Willmore Chrysoula Leontiou Dr Michael Tilby Professor Caroline Austin et al.	Differences in the longevity of topo IIα and topo IIβ drug-stabilized cleavable complexes and the relationship to drug sensitivity	2004
Dr Michael Tilby	Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis	2004
Dr Michael Tilby	Immunohistochemical detection of melphalan-DNA adducts in colon cancer cells in vitro and human colorectal liver tumours in vivo	2004
Katherine Gould Cally Nixon Dr Michael Tilby	p53 elevation in relation to levels and cytotoxicity of mono- and bifunctional melphalan-DNA adducts	2004
Jessie Jeyapalan Alan Leake Dr Shaheda Ahmed Dr Gabriele Saretzki Dr Michael Tilby et al.	The role of telomeres in etoposide induced tumor cell death	2004
Nidal Boulos Professor Andrew Pearson Dr Michael Tilby Professor John Lunec	1p deleted neuroblastoma cells differentiate following chromosome 1 reintroduction	2003
Jessie Jeyapalan Dr Michael Tilby Professor Thomas von Zglinicki	Cisplatin induced neuroblastoma cell death and the involvement of telomeres	2003
Ali Azim-Araghi Dr Michael Tilby	Combination of ICP-MS and ion exchange chromatography permits analyses of specific cis-platin DNA modifications formed in cancer cells.	2003
Tyrone John Professor Andrew Pearson Professor Alan Calvert Dr Michael Tilby	Determination, by ICP-MS, of background and BBR 3464 induced levels of platinum bound to DNA isolated from blood cells: A comparison of the sensitivity of the Perkin Elmer Sciex Elan 6000 and the thermofinnigan Neptune instruments	2003
Dr Michael Tilby	Quantification of DNA adducts in individual cells by immunofluorescence: Effects of variation in DNA conformation	2003
Tyrone John Professor Alan Calvert Dr Michael Tilby	Sensitive determination of BBR 3464 and cisplatin DNA adduct levels in clinical samples using ICP-MS and PIMMS	2003
Tyrone John Dr Michael Tilby	Characterisation and quantification of DNA adducts formed by the platinum drug BBR 3464.	2002
Andrew Jobson Dr Elaine Willmore Dr Michael Tilby Professor Caroline Austin	Characterisation of the roles of Topoisomerase I and II in the mechanism of action of novel anti-tumour agents XR11576 (MLN576) and XR5944 (MLN944)	2002
Timothy Cressey Dr Michael Tilby Professor Herbie Newell	Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines	2002
Dr Elaine Willmore Fiona Errington Dr Michael Tilby Professor Caroline Austin	Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells	2002
Nidal Boulos Professor Andrew Pearson Dr Michael Tilby Professor John Lunec	Functional complementation analysis of chromosome 1 in neuroblastoma	2002
Dr Elaine Willmore Dr Michael Tilby Professor Caroline Austin Professor barbara Durkacz	Potentiation of topoisomerase II poison cytotoxicity in the K562 human leukaemia cell line by the novel DNA-dependent protein kinase inhibitor NU7026	2002
Dr Emma Meczes Professor Andrew Pearson Professor Caroline Austin Dr Michael Tilby	Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin	2002
Ali Azim-Araghi Dr Michael Tilby	Structures of atypical PLATINUM-DNA adducts in certain resistant lung cancer lines	2002
Dr Peter Middleton Dr Michael Tilby	Antibody recognition of melphalan adducts characterized using immobilized DNA: Enhanced alkylation of G-rich regions in cells compared to in vitro	2001
Dr Emma Meczes Professor Andrew Pearson Dr Michael Tilby	Characterisation of the DNA damage recognised by a monoclonal antibody raised against cisplatin-modified DNA	2001
Professor Gareth Veal Dr Cinera Dias Annie Parry Julie Errington Dr Juliet Hale et al.	Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy	2001
Dr Michael Tilby	Measurement of covalent drug-DNA interactions at the nucleotide level in cells at pharmacologically relevant doses	2001
Ali Azim-Araghi Dr Michael Tilby	Mechanisms underlying differences in immunoreactivity of cisplatin DNA adducts formed in certain cancer cells	2001
Ali Azim-Araghi Dr Michael Tilby	Sensitive detection of platinum-bound DNA using ICP-MS and comparison to graphite furnace atomic absorption spectroscopy (GFAAS)	2001
Dr Kay Padget Dr Michael Tilby Professor Caroline Austin	An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2,1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells	2000
Dr Kay Padget Professor Andrew Pearson Dr Michael Tilby Professor Caroline Austin	Camptothecin-stabilised topoisomerase I-DNA complexes in leukaemia cells visualised and quantified in situ by the TARDIS assay (trapped in agarose DNA immunostaining)	2000
Professor Penny Lovat Dr Michael Tilby Professor Archibald Malcolm Professor Andrew Pearson Dr Chris Redfern et al.	Distinct properties of fenretinide and CD437 lead to synergistic responses with chemotherapeutic reagents	2000
Dr Michael Tilby	Evidence for enhanced alkylation of G-rich regions of DNA by melphalan in cells compared to pure solution	2000
Ali Azim-Araghi Dr Michael Tilby	Formation of atypical cisplatin DNA adducts in certain cancer cells	2000
Professor Gareth Veal Dr Cinera Dias Professor Alan Boddy Annie Parry Dr Juliet Hale et al.	In vitro/in vivo correlations of cisplatin-DNA adduct levels in leucocytes of children	2000
Professor Penny Lovat Dr Michael Tilby Professor Archibald Malcolm Professor Andrew Pearson Dr Chris Redfern et al.	Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs	2000
Timothy Cressey Dr Michael Tilby Professor Herbie Newell	Mechanisms of drug specific loss of telomerase activity in testicular cancer cell lines	1999
Fiona Errington Dr Elaine Willmore Dr Michael Tilby Professor Caroline Austin	Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: Analysis of cytotoxicity and cleavable complex formation	1999
Dr Michael Tilby Professor Alan Calvert Professor Herbie Newell	Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels	1999
Dr Emma Meczes Professor Caroline Austin Professor Andrew Pearson Dr Michael Tilby	Synergy studies of etoposide and cisplatin action in neuroblastoma cell lines	1999
Timothy Cressey Dr Michael Tilby Professor Herbie Newell	Comparative effects of cisplatin and melphalan on telomerase activity in a testicular cell line	1998
Timothy Cressey Dr Michael Tilby Professor Herbie Newell	Comparative effects of DNA damaging drugs on telomerase activity in a testicular cell line	1998
Dr Elaine Willmore Dr Adrian Frank Dr Kay Padget Dr Michael Tilby Professor Caroline Austin et al.	Etoposide targets topoisomerase IIα and IIβ in leukemic cells: Isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique	1998
Professor Alan Boddy Professor Andrew Pearson Dr Michael Tilby Professor Herbie Newell	Cisplatin pharmacokinetics in children with cancer	1997
Dr Michael Tilby Professor Andrew Pearson Professor Alan Boddy Professor Herbie Newell	Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy	1997
Dr Adrian Frank Professor Stephen Proctor Dr Michael Tilby	Detection and quantification of melphalan-DNA adducts at the single cell level in hematopoietic tumor cells	1996
Dr Michael Tilby	Effect of quercetin on the genotoxic potential of cisplatin	1996
Dr Michael Tilby Dr Adrian Frank	A monoclonal antibody that recognizes alkali-stabilized melphalan-DNA adducts and its application in immunofluorescence microscopy	1995
Dr Michael Tilby	Differential Sensitivity to the Induction of Apoptosis by Cisplatin in Proliferating and Quiescent Immature Rat Thymocytes Is Independent of the Levels of Drug Accumulation and DNA Adduct Formation	1994
Professor Alan Boddy Professor Andrew Pearson Dr Michael Tilby Professor Herbie Newell	The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in pediatric patients: A review.	1994
Dr Michael Tilby Professor Herbie Newell	Application of a sensitive immunoassay to the study of DNA adducts formed in peripheral blood mononuclear cells of patients undergoing high-dose melphalan therapy	1993
Dr Andrew Hall Dr Michael Tilby	Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies	1992